Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss - Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss - Regeneron Pharmaceuticals (NASDAQ:REGN)

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly dosing period. RVO is a blockage in one of the veins that drain blood from the retina, causing blood and fluid to leak and potentially leading to vision loss. The FDA als…

With new approvals, Regeneron’s higher-dose Eylea gets more competitive

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

FDA Approves 8-mg Aflibercept Injection for Macular Edema Linked to Retinal Vein Occlusion

The U.S. Food and Drug Administration (FDA) has approve […] The post FDA Approves 8-mg Aflibercept Injection for Macular Edema Linked to Retinal Vein Occlusion first appeared on GeneOnline News. The post FDA Approves 8-mg Aflibercept Injection for Macular Edema Linked to Retinal Vein Occlusion appeared first on GeneOnline News.

FDA Approves Aflibercept Injection to Treat Patients With Macular Edema Following RVO

FDA approves an 8-mg aflibercept injection for macular edema following retinal vein occlusion (RVO), offering flexible dosing options for improved patient care.

FDA Approves Eylea HD for Retinal Vein Occlusion (RVO); Expands Dosing Intervals

The FDA has approved Regeneron's Eylea HD (aflibercept) Injection 8 mg for the treatment of macular edema following retinal vein occlusion (RVO). The approval includes dosing intervals of up to every 8 weeks after an initial monthly dosing period. In addition, the FDA has cleared a monthly (every 4-week) dosing option for Eylea HD across all of its approved indications, which include wet age-related macular degeneration (AMD), diabetic macular e…

FDA approves Eylea HD for retinal vein occlusion

Eylea HD offers two dosing options for patients with retinal vein occlusion: 8-week and 4-week dosing intervals.